During the past decade, Jahn Ferenc Del-Pesti Korhaz es Rendelointezet conducted 33 clinical trials. In the 10-year time frame, 33 clinical trials started and 15 clinical trials were completed, i.e. on average, 45.5% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 9 clinical trials were completed. i.e. 56.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Jahn Ferenc Del-Pesti Korhaz es Rendelointezet" #1 sponsor was "Hoffmann-La Roche" with 6 trials, followed by "Boehringer Ingelheim" with 3 trials sponsored, "Alkahest, Inc." with 2 trials sponsored, "Amgen" with 2 trials sponsored and "Bayer" with 2 trials sponsored. Other sponsors include 23 different institutions and companies that sponsored additional 30 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Jahn Ferenc Del-Pesti Korhaz es Rendelointezet" #1 collaborator was "Astellas Pharma Inc" with 1 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator, "Cook Group Incorporated" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "Medpace, Inc." with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Jahn Ferenc Del-Pesti Korhaz es Rendelointezet" are "Multiple Sclerosis" (6 trials), "Multiple Sclerosis, Primary Progressive" (2 trials), "Prostate Cancer" (2 trials), "Urinary Tract Infections" (2 trials) and "Wet Age-related Macular Degeneration" (2 trials). Many other conditions were trialed in "Jahn Ferenc Del-Pesti Korhaz es Rendelointezet" in a lesser frequency.

Most popular intervention types in "Jahn Ferenc Del-Pesti Korhaz es Rendelointezet" are "Drug" (37 trials), "Other" (4 trials), "Biological" (3 trials), "Device" (2 trials) and "Radiation" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "Ocrelizumab" (4 trials), "ALK4290" (2 trials), "Mavenclad®" (2 trials) and "Abiraterone acetate (AA)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Jahn Ferenc Del-Pesti Korhaz es Rendelointezet" are 38 trials for "All" genders and 5 trials for "Male" genders.

Currently, there are NaN active trials in "Jahn Ferenc Del-Pesti Korhaz es Rendelointezet". undefined are not yet recruiting, 8 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 23 completed trials in Jahn Ferenc Del-Pesti Korhaz es Rendelointezet, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Jahn Ferenc Del-Pesti Korhaz es Rendelointezet, 1 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 29 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 1 trials that are defined as “Not Applicable".

Jahn Ferenc Del-Pesti Korhaz es Rendelointezet has several departments that took part in Clinical trials: "Jahn Ferenc Del-pesti Korhaz es Rendelointezet, Neurologiai Osztaly" - 2 trials, "Jahn Ferenc Dél Pesti Hospital, Urology" - 2 trials